Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals. Read why TAK stock is a hold.

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, ...

Takeda is making waves in data and artificial intelligence (AI) with Informatica and AWS: 90% of data moved to the cloud, 40% higher productivity and millions saved in IT overhead. Discover how ...

Lottie Woad's first round as a professional ends with the 21-year-old taking an early share of the lead at the Women's ...

Costa Saroukos, who became Takeda’s global finance chief in 2018, discusses why moving fast after an acquisition is crucial in melding company cultures and cutting back debt.